

Special Issue

Challenges of Radiotherapy for Head and Neck Cancer

Message from the Guest Editor

Even with the refinement of surgical techniques, and the introduction of new systemic agents and treatment concepts, radiotherapy remains an indispensable part of the therapeutic armamentarium in head and neck cancer. Thus, the purpose of this Special Issue is to present the novelties and new directions in the field of radiotherapy for head and neck cancer that are already in use or will potentially play an important role in the future. We welcome original research articles or comprehensive review articles that focus on the possibilities of modulation of radiotherapy intensity or its toxicity, new therapeutic combinations, modifications of the tumor microenvironment, technological innovations, and the potential role of artificial intelligence in radiotherapy to achieve better therapeutic results. Hopefully, such a collection of studies will contribute to a clearer picture of what our expectations should be from radiotherapy in head and neck cancer now and in the future.

Guest Editor

Prof. Dr. Primož Strojan

Department of Radiation Oncology, Institute of Oncology, Zaloška 2,
1000 Ljubljana, Slovenia

Deadline for manuscript submissions

closed (30 November 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/156709

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)